Published in Metabolism on May 14, 2013
DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res (2015) 0.93
Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Semin Immunopathol (2015) 0.90
Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism. J Biol Chem (2014) 0.86
Do incretins improve endothelial function? Cardiovasc Diabetol (2014) 0.80
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol (2014) 0.80
Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts. Am J Physiol Cell Physiol (2016) 0.78
Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies. World J Gastroenterol (2014) 0.78
New research developments and insights from Metabolism. Metabolism (2014) 0.76
Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats. Am J Physiol Endocrinol Metab (2016) 0.75
Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice. AAPS J (2015) 0.75
Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury. Hypertension (2017) 0.75
Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms. J Endocrinol Invest (2017) 0.75
Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 9.77
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest (1998) 5.95
Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell (1999) 4.55
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation (2008) 4.22
Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A (2001) 3.88
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab (2004) 3.65
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation (2004) 3.51
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail (2006) 2.69
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes (2005) 2.64
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58
Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab (2004) 2.21
Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion (1995) 2.05
Akt takes center stage in angiogenesis signaling. Circ Res (2000) 1.96
Diabetic retinopathy and angiogenesis. Curr Diabetes Rev (2009) 1.92
Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes (2006) 1.89
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism (2001) 1.87
New roles for Src kinases in control of cell survival and angiogenesis. Cell (2000) 1.83
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab (2003) 1.66
Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis (2007) 1.55
Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol (2010) 1.53
Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord (1997) 1.33
Microvascular modifications in diabetic retinopathy. Curr Diab Rep (2011) 1.24
Role of c-Src in regulation of endothelial nitric oxide synthase expression during exercise training. Am J Physiol Heart Circ Physiol (2002) 1.23
GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism (2012) 1.22
Update on incretin hormones. Ann N Y Acad Sci (2011) 1.15
Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor. Cardiovasc Res (2007) 1.07
The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism (2004) 1.05
Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol Oncol (2011) 1.03
Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism (2011) 1.02
Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism (2012) 0.99
Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases. Cardiovasc Res (2012) 0.96
Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med (2012) 0.94
Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol (2012) 0.93
Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. Exp Diabetes Res (2012) 0.91
Intensive practical lifestyle intervention improves endothelial function in metabolic syndrome independent of weight loss: a randomized controlled trial. Metabolism (2011) 0.89
GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. Regul Pept (2011) 0.88
Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism (2010) 0.88
Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res (2012) 0.87
VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment? Metabolism (2012) 0.85
Mechanisms responsible for excess weight loss after bariatric surgery. J Diabetes Sci Technol (2011) 0.84
Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice. Metabolism (2010) 0.82
Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic β-cells. Metabolism (2011) 0.81
pp60(c-src) modulates microvascular endothelial phenotype and in vitro angiogenesis. Exp Mol Pathol (2001) 0.80
Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. Diabetes Res Clin Pract (2013) 0.79
Prevalence and predictors of abnormal arterial function in statin-treated type 2 diabetes mellitus patients. Metabolism (2011) 0.77
Exendin-4 regulates GLUT2 expression via the CaMKK/CaMKIV pathway in a pancreatic β-cell line. Metabolism (2010) 0.77
Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A (2009) 6.67
Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer (2007) 5.57
Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med (2004) 4.87
FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism (2012) 3.61
Dietary patterns and risk of mortality from cardiovascular disease, cancer, and all causes in a prospective cohort of women. Circulation (2008) 3.56
Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation (2009) 3.47
Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst (2005) 3.22
Leptin in immunology. J Immunol (2005) 2.62
Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care (2004) 2.55
The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest (2003) 2.42
Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr (2007) 2.40
Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab (2003) 2.25
Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr (2009) 2.22
Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab (2013) 2.16
Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab (2003) 2.09
Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev (2010) 2.09
Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab (2007) 2.07
Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: a prospective cohort study. Diabetes Care (2007) 2.06
Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care (2007) 2.04
The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology (2002) 2.03
Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med (2008) 2.01
Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med (2010) 2.00
Sleep duration and snoring in relation to biomarkers of cardiovascular disease risk among women with type 2 diabetes. Diabetes Care (2007) 1.99
Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev (2007) 1.95
Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. Nat Clin Pract Endocrinol Metab (2006) 1.88
Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab (2004) 1.86
Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab (2003) 1.84
Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism (2010) 1.81
Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab (2005) 1.81
The role of adiponectin in cancer: a review of current evidence. Endocr Rev (2012) 1.78
Leptin and reproduction: a review. Fertil Steril (2002) 1.68
Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab (2003) 1.65
Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut (2012) 1.65
Coffee drinking and risk of endometrial cancer--a population-based cohort study. Int J Cancer (2009) 1.63
Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res (2003) 1.62
Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab (2006) 1.61
Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab (2004) 1.61
Relationship of leptin to bone mineralization in children and adolescents. J Clin Endocrinol Metab (2003) 1.58
Neonatal leptin levels are strongly associated with female gender, birth length, IGF-I levels and formula feeding. Clin Endocrinol (Oxf) (2005) 1.57
Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab (2006) 1.55
Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet (2005) 1.55
Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care (2008) 1.51
Circulating melanin-concentrating hormone, agouti-related protein, and alpha-melanocyte-stimulating hormone levels in relation to body composition: alterations in response to food deprivation and recombinant human leptin administration. J Clin Endocrinol Metab (2004) 1.51
Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism (2011) 1.51
Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab (2006) 1.47
Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci U S A (2006) 1.46
Leptin in human physiology and therapeutics. Front Neuroendocrinol (2010) 1.46
Predictors of Circulating Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor-Binding Protein-3 in Critical Illness. Crit Care Med (2015) 1.38
Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev (2007) 1.37
Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. Eur J Endocrinol (2013) 1.37
Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes (2002) 1.37
Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes (2002) 1.37
Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism (2013) 1.36
Leptin in humans: lessons from translational research. Am J Clin Nutr (2009) 1.35
Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol (2010) 1.34
Irisin: a renaissance in metabolism? Metabolism (2013) 1.32
Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab (2003) 1.32
Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev (2007) 1.31
Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes (2006) 1.29
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. Am J Physiol Endocrinol Metab (2006) 1.27
Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study. Am J Clin Nutr (2008) 1.27
Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A (2011) 1.26
Insulin resistance and vascular dysfunction in nondiabetic Asian Indians. J Clin Endocrinol Metab (2004) 1.26
Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol (Oxf) (2004) 1.25
Energy homeostasis, obesity and eating disorders: recent advances in endocrinology. J Nutr (2004) 1.24
Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis (2003) 1.24
Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. Atherosclerosis (2006) 1.22
Adiponectin: a link between obesity and cancer. Expert Opin Investig Drugs (2006) 1.20
Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr (2010) 1.20
Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer (2007) 1.20
Leptin in reproduction. Curr Opin Endocrinol Diabetes Obes (2007) 1.19
Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer (2008) 1.18
Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J (2011) 1.16
Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control (2008) 1.15
Gene expression of PPARgamma and PGC-1alpha in human omental and subcutaneous adipose tissues is related to insulin resistance markers and mediates beneficial effects of physical training. Eur J Endocrinol (2009) 1.14
Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation (2012) 1.14
Effects of leptin and adiponectin on pancreatic β-cell function. Metabolism (2011) 1.13
Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care (2007) 1.13
Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. J Clin Endocrinol Metab (2004) 1.13
Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu Rev Nutr (2009) 1.13
Leptin and soluble leptin receptor levels in plasma and risk of type 2 diabetes in U.S. women: a prospective study. Diabetes (2009) 1.13
Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism (2013) 1.12
Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control (2008) 1.11
Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes (2011) 1.10
Physical activity and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev (2006) 1.10
Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev (2013) 1.10
High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knock-out (LIRKO) mice. J Biol Chem (2007) 1.09
Responsiveness to peripherally administered melanocortins in lean and obese mice. Diabetes (2004) 1.08
Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) (2006) 1.05
Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clin Pharmacokinet (2008) 1.05
Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One (2013) 1.04
Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition. J Clin Endocrinol Metab (2014) 1.04